-transparent.png){kind=logo}
Transforming growth factor alpha (TGF alpha) has been implicated in the pathogenesis of inhibited bone formation in hypercalcemia of malignancy. We evaluated the effects of infusions of vehicle or TGF alpha (0.25 microgram/h), or parathyroid hormone-related protein (1-34) (PTHrP) (0.025 microgram/h) alone, or a combination of TGF alpha and PTHrP on bone histomorphometry in mice. The peptides were infused for 6 days via Alzet osmotic minipumps. TGF alpha alone, PTHrP alone, or a combination of the two resulted in an increase in bone resorption as well as bone formation parameters. The increase in bone formation with the combination of TGF alpha and PTHrP was significantly greater than that seen with either peptide alone. Therefore, it is unlikely that TGF alpha is the factor responsible for inhibited bone formation in hypercalcemia of malignancy.
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
December 1990,
The American journal of physiology,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
October 1991,
Domestic animal endocrinology,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
July 1993,
The Journal of clinical endocrinology and metabolism,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
November 1991,
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
July 1989,
Endocrinology,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
February 2002,
Molecular and cellular endocrinology,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
March 1993,
Molecular and cellular endocrinology,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
January 1999,
Life sciences,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
June 1998,
Endocrine,
S C Kukreja, and
T J Rosol, and
J J D'Anza, and
S A Wimbiscus
January 1999,
Biology of reproduction,
